- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01885845
Excellent BRASSS-V Drape™ Versus Indirect Measurement Protocol for Measurement of Postpartum Blood Loss
A Comparison of the Excellent BRASSS-V Drape™ and an Indirect Blood Measurement Protocol for the Measurement of Blood Loss During Third Stage of Vaginal Delivery
Postpartum hemorrhage is one of the most common causes of maternal mortality and serious maternal morbidity, especially in the developing world. In India, hemorrhage is a major cause of maternal mortality: A study by the Register General in 1993 showed that 23 percent of all maternal deaths in rural areas were caused by hemorrhage (Sibley, 2005).
The measurement of postpartum blood loss and identification of postpartum hemorrhage are important measures in efforts to prevent and treat postpartum hemorrhage. In recent years, researchers have employed several different methods to measure blood loss in hospital and community-based birth settings. Although research has demonstrated that these laboratory measures are more accurate then visual estimation techniques, no studies have explicitly documented the systematic differences (if any) among different collection modalities. Moreover, only a few of these studies have correlated measured blood loss with changes in hemoglobin levels experienced between the antepartum and postpartum period. The aim of this study is to compare variations in the measurement of blood loss obtained using two popular measurement methods: the Excellent BRASSS-V Drape™ and a modified version of the blood collection method developed by the World Health Organization (WHO).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Postpartum hemorrhage is one of the most common causes of maternal mortality and serious maternal morbidity, especially in the developing world. In India, hemorrhage is a major cause of maternal mortality: A study by the Register General in 1993 showed that 23 percent of all maternal deaths in rural areas were caused by hemorrhage (Sibley, 2005).
The measurement of postpartum blood loss and identification of postpartum hemorrhage are important measures in efforts to prevent and treat postpartum hemorrhage. However, visual estimation of postpartum hemorrhage often leads to underestimation of blood loss and subsequent delays in the seeking or provision of appropriate treatment. In recent years, researchers have employed several different methods to measure blood loss in hospital and community-based birth settings. Although research has demonstrated that these laboratory measures are more accurate then visual estimation techniques, no studies have explicitly documented the systematic differences (if any) among different collection modalities. Moreover, only a few of these studies have correlated measured blood loss with changes in hemoglobin levels experienced between the antepartum and postpartum period. The aim of this study is to compare variations in the measurement of blood loss obtained using two popular measurement methods: the Excellent BRASSS-V Drape™ and a modified version of the blood collection method developed by the World Health Organization (WHO).
We propose a randomized prospective study to compare the measurement of blood loss during the third stage of labor with two different methods: the modified WHO blood measurement protocol and the Excellent BRASSS-V Drape™. Upon admission in the labor ward, study staff will approach all delivering women about participation in the study and seek informed consent. Blood loss will be measured for all consenting women with vaginal deliveries.
Women who agree to participate will be randomized to one of two blood collection techniques: a modified version of the WHO blood measurement protocol or the Excellent BRASSS-V Drape™. Blood loss will be measured from immediately after delivery and cord clamping for a period of at least one hour or until active bleeding stops. The blood loss will then be quantified by the study staff and recorded on the study form. Women will receive the facility's standard care for the management of the third stage of labor and, if applicable, treatment of PPH.
Measures of postpartum hemoglobin levels will be taken at admission for delivery and twenty-four hours post-delivery for a randomly selected sub-set of study participants. Besides the measurement of blood loss and the regular measurement of hemoglobin for a sub-sample of participants, there will be no change to the hospital's standard procedures for labor and delivery.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Pune, Indien
- KEM Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
• Vaginal birth
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: BRASSS-V drape
Immediately after delivery and cord clamping, blood measurement will begin.
The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs.
Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
|
Immediately after delivery and cord clamping, blood measurement will begin.
The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs.
Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
|
Eksperimentel: Indirect weight method
Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped. After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml. |
Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped. After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Mean blood loss
Tidsramme: after delivery to when active bleeding has stopped or at least one hour
|
after delivery to when active bleeding has stopped or at least one hour
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Hillary Bracken, PhD, Gynuity Health Projects
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2.4.7
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Postpartum blødning
-
Université de Reims Champagne-ArdenneIkke rekrutterer endnu
-
University of PennsylvaniaAktiv, ikke rekrutterende
-
Washington University School of MedicineSociety of Family PlanningAfsluttetPostpartum periodeForenede Stater
-
Icahn School of Medicine at Mount SinaiRekrutteringPostpartum RecoveryForenede Stater
-
Nottingham Trent UniversityUniversity of Nottingham; Ministry of Defence, United Kingdom; University... og andre samarbejdspartnereRekrutteringPostpartum periodeDet Forenede Kongerige
-
Woebot HealthScripps Translational Science InstituteAfsluttet
-
University of VigoAfsluttet
-
Herning HospitalAfsluttet
-
London School of Hygiene and Tropical MedicineDepartment for International Development, United Kingdom; Economic and... og andre samarbejdspartnereAfsluttet
-
FHI 360Ghana Health Services; Ministry of Health, ZambiaAfsluttet
Kliniske forsøg med Excellent BRASSS-V Drape™.
-
Vectorious Medical Technologies Ltd.Ikke rekrutterer endnu
-
Vectorious Medical Technologies Ltd.Rekruttering
-
Vectorious Medical Technologies Ltd.Rekruttering
-
Vectorious Medical Technologies Ltd.Horizon 2020 - European CommissionAktiv, ikke rekrutterende
-
Sino Medical Sciences Technology Inc.AfsluttetKoronararteriesygdom | Stabil Angina Pectoris | Ustabil angina pectorisKina
-
Abbott Medical DevicesAfsluttetMyokardieiskæmi | Koronararteriesygdom | Koronar arteriosklerose | Stent trombose | Vaskulær sygdom | Koronararteriestenose | Total koronar okklusion | Koronararterie-restenoseFrankrig, Italien, Norge, Kina, Spanien, Tyskland, Det Forenede Kongerige, Schweiz, Israel, Danmark, Belgien, Østrig, Polen, Australien, Portugal, Argentina, Brasilien, Ungarn, Letland, Holland, Indien, Grækenland, Malaysia, Den Russiske... og mere
-
Abbott Medical DevicesAfsluttet
-
Engeneic Pty LimitedJohns Hopkins UniversityUkendtGlioblastom | Astrocytom, grad IVForenede Stater
-
Abbott Medical DevicesAfsluttetKoronararteriesygdom | Koronar sygdom | Koronar restenoseHolland, Thailand, Israel, Spanien, Italien, Det Forenede Kongerige, Malaysia, Østrig, Frankrig, Tyskland, Polen
-
Massachusetts General HospitalSuspenderetPort-vin bejdseForenede Stater